| Date | Title | Description |
| 26.09.2024 | Araris Biotech expands its IP portfolio |
Founded as spin-off company from the Paul Scherrer Institute (PSI) and ETH Zurich, Araris Biotech has developed AraLinQ, a proprietary antibody-drug conjugate (ADC) technology that enables best-in-class ADCs with significantly enhanced eff... |
| 19.12.2022 | Communiqué de presse: Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie | /EIN News/ -- Sanofi et Innate Pharma étendent leur collaboration sur les anticorps thérapeutiques engageant les cellules Natural Killer en oncologie Sanofi obtient une licence exclusive sur le programme B7H3 ANKETTM d’Innate et des options... |
| 06.01.2022 | INNATE PHARMA OBTAINS EUR28.7M IN NON- DILUTIVE FINANCING IN THE FORM OF STATE GUARANTEED LOANS | Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) ('Innate' or the 'Company') announced that it has obtained EUR28.7M in non-dilutive financing in the form of two loans from Societe Generale and BNP Paribas.
The two loans have an initial... |
| 07.09.2021 | Innate Pharma : Announces Conference Call and Webcast for First Half 2021 Business Update | Marseille, France, Sept. 07, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Wednesday, September 15, 2021, at 2 p.m.... |
| 02.09.2021 | Innate Pharma : Monalizumab and ANKET™ Data Will be Presented at ESMO 2021 Virtual Congress | Marseille, France, Sept. 02, 2021 (GLOBE NEWSWIRE) -- AstraZeneca to present new data on monalizumab in combination with durvalumab in a late-breaking abstract on COAST Phase 2 trial
Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) (“In... |
| 30.08.2021 | Innate Pharma : to Participate in Upcoming Investor Conferences | Marseille, France, Aug. 30, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that members of its senior management team are scheduled to participa... |
| 06.07.2021 | Update on Avdoralimab Phase 2 Force Trial in COVID-19 Patients With Severe Pneumonia | Investigator-sponsored FORCE trial did not meet primary endpoints
Company will stop exploring avdoralimab in COVID-19
Investigator-sponsored avdoralimab clinical trial in inflammation will continue
MARSEILLE, France, July 06, 2021 (GLOBE NE... |
| 22.06.2021 | Innate Pharma : presents preliminary data from TELLOMAK trial showing clinical response for lacutamab in mycosis fungoides | Marseille, June 22, 2021 (GLOBE NEWSWIRE) -- First data set from TELLOMAK establishes safety, clinical responses and skin improvement in patients with mycosis fungoides that express KIR3DL2
Data support continued development of lacutamab fo... |
| 16.06.2021 | INNATE PHARMA
Innate Pharma to Host Virtual Investor Event to Highlight Progress Against Company Strategy | MARSEILLE, France, June 16, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that it will host a virtual investor event on Wednesday, June 23, 202... |
| 10.06.2021 | INNATE PHARMA
Innate Pharma Presents New Data on Next-Generation NK Cell Engager Platform at FOCIS 2021 Annual Meeting | Proprietary, multi-specific NK cell engager platform, ANKET™, to generate next wave of immunotherapy molecules
ANKET is first NK cell engager technology to engage NKp46, CD16, IL-2 variant and tumor antigen in a single tetra-specific molecu... |
| 09.06.2021 | INNATE PHARMA
New Lacutamab Data from TELLOMAK Trial to be Showcased in Oral Presentation at Upcoming 16th International Conference on Malignant Lymphoma | Marseille, France, June 09, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced that preliminary mycosis fungoides data from the Phase 2 TELLOMAK tri... |
| 28.05.2021 | INNATE PHARMA
Innate Pharma : Outcome of Innate Pharma's Annual General Meeting | Marseille, France, May 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) announced the voting results of its shareholders at the Annual General Meeting (“AGM”)... |
| 12.05.2021 | INNATE PHARMA
Innate Pharma Virtual 2021 Annual General Meeting | MARSEILLE, France, May 12, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) has published the convening notice to the Bulletin des Annonces Légales Obligatoires f... |
| 11.05.2021 | INNATE PHARMA
Innate Pharma First Quarter 2021 Report | Lacutamab TELLOMAK trial progresses as KIR3DL2-expressing mycosis fungoides cohort advances to Stage 2 after positive early signal
Company’s first NK cell engager selected by Sanofi as drug candidate for developmentCash position of €181.7 m... |
| 04.05.2021 | INNATE PHARMA
Innate Pharma : Announces Conference Call and Webcast for 2021 First Quarter Business Update | Marseille, France, May 04, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”), today announced that the Company will hold a conference call on Thursday, May 11, 202... |
| 28.04.2021 | INNATE PHARMA
Innate Pharma Files Its 2020 Universal Registration Document (Document D'enregistrement Universel) and 2020 Annual Report on Form 20-F | MARSEILLE, France, April 28, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IPH – ISIN: FR0010331421; Nasdaq: IPHA) (“Innate” or the “Company”) today announced the filing of its 2020 Universal Registration Document (Document d’e... |
| 21.04.2021 | INNATE PHARMA
Innate Pharma : to Hold its Annual General Meeting of Shareholders on May 28, 2021 | The Annual General Meeting will be broadcasted live by the Company
Shareholders are invited to vote at the General Meeting either by mail or by proxy
Marseille, France, April 21, 2021 (GLOBE NEWSWIRE) -- Innate Pharma SA (Euronext Paris: IP... |
| 17.03.2021 | INNATE PHARMA
Innate Pharma : Annual financial announcement | INNATE PHARMA REPORTS FULL YEAR 2020 FINANCIAL1
RESULTS AND BUSINESS UPDATE
• Lacutamab received PRIME designation from the European Medicines Agency in Sezary Syndrome; clinical development program advances in mycosis fungoides and periphe... |
| 24.02.2021 | Nouveau nombre d'actions et de droits de vote d'Innate Pharma au 1er février 2021 | Marseille, 24 févr. 2021 (GLOBE NEWSWIRE) -- Conformément aux articles L. 233-8 II du Code de Commerce et 223-16 du règlement général de l’Autorité des marchés financiers (l’« AMF »), Innate Pharma SA (la « Société » - Euronext Paris : FR00... |
| 24.02.2021 | Number of shares and voting rights of Innate Pharma as of February 1, 2021 | MARSEILLE, France, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regu... |
| 24.02.2021 | Number of shares and voting rights of Innate Pharma as of February 1, 2021 | Marseille, Feb. 24, 2021 (GLOBE NEWSWIRE) -- Pursuant to the article L. 233-8 II of the French “Code de Commerce” and the article 223-16 of the French stock-market authorities (Autorité des Marchés Financiers, or “AMF”) General Regulation, ... |
| 15.03.2019 | AstraZeneca vet Jennifer Butler takes charge of Innate Pharma's US biz; C4 raids NIBR | → France’s Innate Pharma has wooed AstraZeneca vet Jennifer Butler to lead the US operations it has set up after acquiring Lumoxiti from the British drugmaker in a rich add-on collaboration deal. Butler’s official ti... |
| 23.10.2018 | AstraZeneca is paying Innate Pharma at least $242M in near-term cash to sew up rights to monalizumab-plus | Just 2 days after rolling out a positive snapshot of activity for its NKG2A immune checkpoint inhibitor monalizumab at ESMO, Innate Pharma SA (Euronext: $IPH) has struck a rich add-on collaboration deal with AstraZenec... |
| 28.10.2011 | Earnings roundup: Bristol-Myers Squibb and Celgene | Among the drugs in the pipeline are a new blood clot preventer called Eliquis developed with Pfizer and dapagliflozin for type 2 diabetes — the FDA has delayed making a decision until January next year.
Still, its research, marketing and ta... |
| - | Earnings roundup: Bristol-Myers Squibb and Celgene | Bristol-Myers Squibb (NYSE:BMS) posted net income of $969 million in the third quarter of 2011 and is optimistic about its pipeline of drugs approaching or in phase 3 trials as they near approval. It may have something to do with its blockb... |
